CRSP - What's Going On With Crispr Therapeutics Stock? | Benzinga
Crispr Therapeutics (NASDAQ:CRSP) shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Here's a look at what's going on.
What To Know:
Crispr Therapeutics’ shares have risen nearly 37% over the past month following the FDA approval of Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older on Jan. 16.
On Tuesday, Crispr Therapeutics announced that it has entered into an agreement for the sale of approximately $280 million of its common shares to a select group of institutional investors in a registered direct offering, at a price per share of $71.50, representing a premium of greater than 10% to the stock's 30-day volume-weighted average price.
“We are well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabetes, and further accelerate our auto-immune and in ...